According to the reviewed literature, PSMA PET/CT may, therefore, play a role in the future evaluation of patients with HR-negative tumor phenotypes, such as BC TPN, both for staging and monitoring treatment response to selective angiogenesis inhibition. The gene discussed is FOLH1; the disease is breast cancer.